What are the adverse effects of high-dose intravenous vitamin C (3 g per day)?

Adverse Effects of High-Dose IV Vitamin C (3 g/day)

At 3 grams per day, intravenous vitamin C is generally safe with minimal adverse effects in most patients, but specific high-risk populations require careful screening and monitoring to prevent serious complications.

General Safety Profile

The 3 g/day dose you're asking about falls within the recommended repletion range (2-3 g/day IV) during critical illness according to ESPEN guidelines 1. This dose is substantially lower than the very high doses (50-200 mg/kg/day) used in some clinical trials, which have shown more concerning safety signals.

Common Adverse Effects

Based on FDA drug labeling and clinical evidence:

• Allergic reactions (including rare anaphylactic reactions) may occur in patients hypersensitive to vitamin C or other components 2
• Mild gastrointestinal symptoms - lethargy/fatigue (most common), nausea
• Vein irritation/phlebitis at infusion sites 3
• Change in mental status (reported in 21/9,328 patients in one survey) 3

The overall incidence of adverse events at standard repletion doses appears low. In a comprehensive scoping review, adverse event rates in double-blind RCTs were either identical to or numerically lower than placebo groups 4.

Critical High-Risk Populations Requiring Screening

1. Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency - ABSOLUTE CONTRAINDICATION

Screen all patients for G6PD deficiency before initiating IV vitamin C, especially males and those of African, Mediterranean, or Asian descent. Three documented cases of severe hemolysis occurred in G6PD-deficient patients 4. A 2022 meta-analysis found that 78.6% of hemolysis cases occurred in G6PD-deficient patients, with complications developing within 3 days in most cases 5. This can be fatal.

2. Renal Impairment

• Five cases of oxalate nephropathy have been reported with high-dose IV vitamin C 4
• Monitor renal function (creatinine, eGFR) before and during treatment
• Exercise extreme caution in patients with pre-existing chronic kidney disease
• The kidney excretes vitamin C, so doses should be reduced or avoided in renal failure 6

3. Iron Overload Conditions - RELATIVE CONTRAINDICATION

Avoid vitamin C supplementation in patients with hemochromatosis or iron overload states 7, 8, 7. Vitamin C acts as a pro-oxidant in iron-overloaded patients by:

• Mobilizing iron from reticuloendothelial stores
• Increasing iron availability and free radical generation
• Potentially causing acute cardiac deterioration (documented in thalassemia major patients) 7

If supplementation is absolutely necessary, limit to ≤500 mg daily and only after discussing with a physician 7.

4. Cancer Patients on Chemotherapy

Recent evidence raises concerns:

• A 2015 study showed vitamin C may promote thrombosis through procoagulant activation of red blood cells, with cancer patients showing increased sensitivity 9
• The 2026 VICTORY trial in burn patients (using 50 mg/kg q6h) was stopped early for futility/harm, showing increased 28-day mortality (15.0% vs 7.6%, P=0.001) 10
• The 2022 LOVIT trial in septic patients showed higher risk of death or persistent organ dysfunction (44.5% vs 38.5%, P=0.01) 11

Specific Monitoring Requirements

Before Starting Treatment:

• G6PD enzyme level (mandatory)
• Baseline renal function (creatinine, eGFR)
• Iron studies if hemochromatosis suspected
• Glucose monitoring capability (see below)

During Treatment:

• Glucometer interference: Vitamin C can cause falsely elevated glucose readings on some point-of-care devices 4. Use laboratory-based glucose measurements if high readings are obtained.
• Hypernatremia: Five cases reported with high-dose therapy 4
• Renal function monitoring, especially if using doses >3 g/day or prolonged therapy
• Watch for signs of hemolysis (dark urine, jaundice, falling hemoglobin)

Dose-Specific Considerations

At 3 g/day, you are at the upper end of the ESPEN-recommended repletion dose 1:

• This dose is appropriate for critical illness, continuous renal replacement therapy (CRRT), or chronic oxidative stress conditions
• It is well below the very high doses (≥6 g/day or ≥75 mg/kg/day) associated with most serious adverse events
• A 2010 survey of CAM practitioners found that at average doses of 28 grams per treatment, only 101 of 9,328 patients (1.1%) experienced side effects, mostly minor 3

Clinical Context Matters

The safety profile differs dramatically by clinical context:

• Sepsis/Critical Illness: Recent high-quality RCTs show potential harm at very high doses. The 2022 LOVIT trial demonstrated increased mortality with 50 mg/kg q6h 11
• Burn Injury: The 2026 VICTORY trial showed harm with high-dose therapy 10
• Cancer/Supportive Care: Phase I/II studies show good tolerability at moderate doses, but thrombotic risk exists 9, 12, 13
• COVID-19: A 2024 study of 10 g/day for 3 days showed good safety with no adverse reactions 14

Practical Algorithm for Safe Use

1. Screen for absolute contraindications: G6PD deficiency, severe renal impairment
2. Screen for relative contraindications: Iron overload, active thrombosis risk
3. Use laboratory glucose monitoring (not point-of-care devices)
4. Limit duration: 3-7 days for acute conditions; reassess need for continuation
5. Monitor: Renal function, hemoglobin, signs of hemolysis
6. Dilute appropriately: In normal saline or glucose to minimize vein irritation 1

Key Pitfall to Avoid

Do not assume "it's just a vitamin" is safe for everyone. The most serious adverse events (hemolysis, oxalate nephropathy, thrombosis) occur in predictable high-risk populations that can be identified with simple screening tests. The difference between safe and harmful use is proper patient selection and monitoring.